Working… Menu

Pulsed Dye Laser Treatment of Acne Vulgaris

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01052246
Recruitment Status : Completed
First Posted : January 20, 2010
Last Update Posted : January 20, 2010
Information provided by:
Laserklinik Karlsruhe

Brief Summary:

The results of pulsed dye laser (PDL) treatment of acne vulgaris published so far are controversial: Whereas Seaton et al. described a marked improvement of mild-to-moderate acne after low-fluence pulsed-dye laser therapy, Orringer et al. were unable to replicate said results in a similar, albeit not identical, study design. More recently published studies failed to resolve the controversy, varying in terms of treatment procedure(s) as well as results.

While published results are certainly promising enough to be followed up by independent research, they are insufficient to justify the abdication of methods with proven efficacy. Considering patient treatment ethics and the short 'window of opportunity' for scar prevention when active inflammatory lesions are present, the investigators planned the adjuvant application of the PDL in the present study, providing all patients with the well established and evidentially effective modality of a fixed-combination clindamycin 1%-benzoyl peroxide 5% hydrating gel (C/BPO). The goal of the study was the assessment of the efficacy and safety of a low-fluence PDL treatment in addition to C/BPO in patients with facial inflammatory acne.

Condition or disease Intervention/treatment Phase
Acne Vulgaris Drug: Fixed combination of clindamycin 1% + benzoyl peroxide 5% Device: Pulsed dye laser Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Pulsed Dye Laser as an Adjuvant Treatment Modality in Acne Vulgaris - a Randomized Controlled Single Blinded Trial
Study Start Date : October 2008
Actual Primary Completion Date : June 2009
Actual Study Completion Date : September 2009

Arm Intervention/treatment
Experimental: Clindamycin 1% + benzoyl peroxide 5% & pulsed dye laser Device: Pulsed dye laser

Patients randomized in the experimental group received two additional treatments with a pulsed dye laser using the following parameters:

  • Wavelength 585 nm
  • Energy fluence 3 J/cm2
  • Pulse duration 0.35 msec
  • Spot size 7 mm

Active Comparator: Clindamycin 1% + benzoyl peroxide 5% Drug: Fixed combination of clindamycin 1% + benzoyl peroxide 5%
Topical monotherapy with a fixed combination of 1% clindamycin and 5% benzoyl peroxide hydrating gel (Duac® Akne Gel, Stiefel Laboratorium GmbH, Offenbach, Germany). In order to provide standardized condition within the sample, the gel was applied on the whole face regardless of the lesion location. The gel was applied once per day in the evening throughout the observation period and left in place overnight.

Primary Outcome Measures :
  1. Investigator's Static Global Assessment [ Time Frame: day 0, day 14, day 28 ]
  2. Lesions count [ Time Frame: day 0, day 28 ]

Secondary Outcome Measures :
  1. Dermatology Life Quality Index [ Time Frame: day 0, day 28 ]
  2. Documentation of side effects [ Time Frame: day 28 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adolescents and adults with moderate inflammatory acne vulgaris (ISGA degrees 2-4)
  • Fitzpatrick skin type I-III

Exclusion Criteria:

  • Atopic dermatitis
  • Oral antibiotics during the last 4 weeks prior to enrolment
  • Oral isotretinoin during the last 52 weeks prior to enrolment
  • Oral contraceptives during the last 26 weeks prior to enrolment
  • Topical acne therapeutics during the last 4 weeks prior to enrolment
  • Diagnosis or anamnestic indication of a regional enteritis, Morbus Crohn or antibiotics-associated colitis
  • Laser surgery interventions within the treatment region during the last 12 weeks prior to enrolment
  • Coagulation anomalies or anticoagulant treatment
  • Photo-sensitizing medication (e. g., tetracycline, gold)
  • Pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01052246

Layout table for location information
Laserklinik Karlsruhe
Karlsruhe, Germany, D-76133
Sponsors and Collaborators
Laserklinik Karlsruhe
Layout table for investigator information
Principal Investigator: Syrus Karsai, MD Laserklinik Karlsruhe
Layout table for additonal information
Responsible Party: Syrus Karsai/Principal investigator, Laserklinik Karlsruhe Identifier: NCT01052246    
Other Study ID Numbers: LK_08_2009
First Posted: January 20, 2010    Key Record Dates
Last Update Posted: January 20, 2010
Last Verified: January 2010
Keywords provided by Laserklinik Karlsruhe:
acne vulgaris
laser surgery
pulsed dye lasers
benzoyl peroxidase
randomized controlled trial
Additional relevant MeSH terms:
Layout table for MeSH terms
Acne Vulgaris
Acneiform Eruptions
Skin Diseases
Sebaceous Gland Diseases
Clindamycin palmitate
Clindamycin phosphate
Benzoyl Peroxide
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Dermatologic Agents